Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan;39(1):e25126.
doi: 10.1002/jcla.25126. Epub 2024 Dec 18.

Detection of Circulating Tumor Cells in the Prognostic Significance of Patients With Breast Cancer: A Retrospective Study

Wanwen Xu  1 , Feng Yuan  2
Affiliations

Detection of Circulating Tumor Cells in the Prognostic Significance of Patients With Breast Cancer: A Retrospective Study

Wanwen Xu et al. J Clin Lab Anal. 2025 Jan.

Abstract

Background: Breast cancer (BC) is an aggressive tumor. Circulating tumor cells (CTCs) are a potential biomarker for the prognosis of cancer patients. This study aimed to explore the prognostic significance of CTCs in patients with BC.

Methods: Retrospectively, 108 BC patients were collected between January 2011 and December 2019, while 10 patients with benign nodules were included as controls. CTCs with different phenotypes of patients were isolated using CanPatrol and tricolor RNA in situ hybridization (RNA-ISH) methods. Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2) levels were measured by immunohistochemistry (IHC). The progression-free survival (PFS) was calculated using the Kaplan-Meier method. Independent risk factors for BC recurrence were determined by Cox proportional risk regression analysis.

Results: The higher the cancer stage (p = 0.00), the higher the ki-67 expression level (p < 0.01), and the lower the histologic grade (p < 0.01), the higher the number of CTCs. The PFS of patients with high CTCs was shorter than that of patients with low CTCs (p < 0.05). Total CTCs (≥ 6) and positive mesenchymal CTCs (MCTCs) were also associated with recurrence and metastasis.

Conclusions: Total CTCs in BC patients have an independent influence on PFS reduction. Higher total CTCs and MCTCs in peripheral blood are biomarkers for predicting the prognosis of BC patients. HER-2 high expression is also associated with the prognosis of the disease.

Keywords: breast cancer; circulating tumor cells; metastasis; progression‐free survival; recurrence; triple negative breast cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Images of CTCs in breast cancer by CanPatrol and the RNA in situ hybridization technique. (A) Epithelial CTCs: EpCAM and CK8/18/19 genes were labeled with AF594 immunofluroresence dye conjugation (red dots). (B) Mesenchymal CTC: Vimentin and Twist genes were labeled with AF488 immunofluroresence dye conjugation (green dots). (C) Mixed CTCs: the cellular nucleus was stained with 6‐diamidino‐2‐phenylindole (DAPI). All pictures were taken by an immunofluroscence microscope at 100× magnification. CTCs, circulating tumor cells.
FIGURE 2
FIGURE 2
ROC curve determination of the CTC cutoff value for differentiating clinical significance. This graph shows the ROC curve of total CTCs in 108 BC patients and 10 patients with benign nodules. It determined sensitivity and specificity of CTCs at 6.0/5 mL of blood as a cutoff. AUC, area under the ROC curve; CTC, circulating tumor cells; ROC, receiver operating characteristic.
FIGURE 3
FIGURE 3
Comparison of progression‐free survival (PFS) in patients with total CTCs, epithelial CTCs, Mixed CTCs, and mesenchymal CTCs (MCTCs) by Kaplan–Meier curves. (A) Total CTCs, (B) epithelial CTCs, and (C, D) mixed MCTCs and MCTCs. CTC, circulating tumor cell; MCTC, mesenchymal CTC.
FIGURE 4
FIGURE 4
PFS comparison of patients with hormone receptor expression by Kaplan–Meier curves. (A) Estrogen receptor (ER), (B) progesterone receptor‐PR, (C) ER, PR, and HER2 triple positive (TR+), and (D) triple negative breast cancer (TNBC). PFS, progression‐free survival.
See this image and copyright information in PMC

References

    1. Bray F., Laversanne M., Sung H., et al., “Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 74, no. 3 (2024): 229–263. - PubMed
    1. Watkins Elyse J., “Overview of breast cancer,” JAAPA: official journal of the American Academy of Physician Assistants 32, no. 10 (2019): 13–17. - PubMed
    1. Kallel M., Elloumi F., Khabir A., et al., “Breast Cancer in Young Women in Southern Tunisia: Anatomical Study and Clinical Prognostic Factors: About a Series of 83 Patients,” Reports of Practical Oncology and Radiotherapy 20, no. 3 (2015): 155–160. - PMC - PubMed
    1. Truin W., Voogd A. C., Vreugdenhil G., van der Heiden‐van der Loo M., Siesling S., and Roumen R. M., “Effect of Adjuvant Chemotherapy in Postmenopausal Patients With Invasive Ductal Versus Lobular Breast Cancer,” Annals of Oncology 23, no. 11 (2012): 2859–2865. - PubMed
    1. Sotiriou C. and Pusztai L., “Gene‐Expression Signatures in Breast Cancer,” New England Journal of Medicine 360, no. 8 (2009): 790–800. - PubMed